Ventus Therapeutics

Ventus Therapeutics

Edit info

  • Founded: 2019
  • Location: Waltham, MA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: Immunology, Rheumatology
  • Drug types: IMM, RHU, DRM, NEU, GI, HEP, NPH, CVV
  • Lead product: VENT-03
  • Funding: $140M C Feb 2022; $100M Apr 2021; $60M A May 2020
  • Investors: Versant Ventures


ventustx.com

linkedin.com

job board


Business:

Small Molecules targeting proteins in the inflammasome and nucleic acid sensing signaling pathways

Drug notes:

VENT-02 Clin1 neuro; VENT-01 Clin0 renal, cardiovascular, hepatic; VENT-05 RD undisclosed; VENT-04 RD various

About:

Ventus Therapeutics uses structural biology and computational chemistry tools to address a wide range of diseases, including immunology, inflammatory, and neurological disorders. Their drug discovery platform models all protein conformations to identify druggable pockets in order to create a “blueprint” for developing small molecule therapeutics. Through their platform, Ventus can virtually screen libraries of compounds to identify molecules that resemble the “blueprint”and then optimize them for improved efficacy. They aim to address current limitations in industry. Their expertise in protein engineering, structure determination, and expression enables them to confront previously challenging targets like the inflammasome and nucleic acid sensing pathways.

Ventus Therapeutics
Senior Manager, Clinical Biomarker Operations
United States|8 days ago
Apply
Ventus Therapeutics
Senior Director, Quality Assurance
United States|Not provided


© 2025 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com